Abstract:Abstract Introduction Burn patients have altered pharmacokinetics, in part, due to a high incidence of augmented renal clearance (ARC). Augmented renal clearance is associated with subtherapeutic antibiotic concentrations necessitating dosing regimens that are greater than FDA approved doses. The objective of this cohort analysis was to assess antibiotic concentrations in patients with ARC specifically when real-time therapeutic drug monitoring was not available for the antibiotic. Methods This retrospective descriptive cohort was performed at an ABA verified burn center. All patients with an antibiotic serum concentration measured between 2/2022 and 7/2023 and confirmed ARC were included. Patients were excluded if the only antibiotic concentration available was an aminoglycoside or vancomycin. Results In all, 10 patients (90% male) had 15 non-real time antibiotic concentration assessments. The median (range) age, weight, TBSA, day since injury, serum creatinine and urine collection creatinine clearance corresponding to the drug concentration were 38 years (18-53), 85 kg (51-190), 24% (3-68.25), 13 days (6-32), 0.77 mg/dL (< 0.2-1.53), and 200 mL/min (96-336), respectively. The most common antibiotic concentration assessed was piperacillin (PIP, n=9), followed by meropenem (MER, n=3), cefepime (n=2), and linezolid (n=1). Piperacillin/tazobactam was administered as 22.5g/day continuous infusion and resulted in a median (range) PIP concentration of 43.7 mg/L (25-117). A single outlier of 117 mg/L occurred in a patient who was no longer in ARC, but reexhibited ARC days later and had a follow-up PIP concentration of 32 mg/L. Two MER concentrations representing a 2g every 8 hours using a 6 hour infusion were 13.9 mg/L at the end of infusion and 7.3 mg/L one hour after infusion. MER 1g every 8 hours with a 3 hour extended infusion resulted in a trough concentration of 1.2 mg/L. Cefepime 2g every 6 hours with a 3 hour extended infusion resulted in a peak and trough of 43.8 and 29.6 mg/L. Linezolid 600mg orally every 8 hours resulted in a trough of 4.21 mg/L. No adverse events were identified. Conclusions Burn patients with ARC may require more aggressive dosing regimens to reach adequate antibiotic concentrations. A large prospective study is required to identify appropriate antibiotic dosing strategies to overcome pharmacokinetic alterations in this population, especially in the setting of pathogens with high minimum inhibitory concentrations. Applicability of Research to Practice Although antibiotic target concentrations have not been established in the burn population, this cohort suggests antimicrobial regimens should be adjusted in burn patients with ARC. The lack of timely therapeutic drug monitoring for most antimicrobials may hamper patient specific dosing regimens to adequately treat infectious pathogens with elevated minimum inhibitory concentrations.

Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.

[Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase]

Pharmacokinetic/Pharmacodynamic Analysis Of Imipenem In Plasma And Peritoneal Liquid In Chinese Patients With Perforated Upper Gastrointestinal Tract

High-Volume Hemodiafiltration with Step-Down Approach versus Standard-of-Care Continuous Renal Replacement Therapy Approach in Critically Ill Burn Patients

Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients

Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation

High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial

A Multicenter, Retrospective Outcome Analysis of Vancomycin Area Under the Curve Versus Trough-Based Dosing Strategies in Patients With Burn OR Inhalational Injuries (MONITOR)

A Multicenter Clinical Trial of Piperacillin/tazobactam in Burn Infection

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

Population Pharmacokinetics of Vancomycin in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.

6 A Multicenter Outcome Analysis of Vancomycin Dosing Strategies in Burn Patients

Population Pharmacokinetics and Dosing Simulation of Vancomycin Administered by Continuous Injection in Critically Ill Patient

510 Antibiotic Serum Concentrations in Burn Patients with Augmented Renal Clearance and Adjusted Regimens

Mathematical Model of Volume Kinetics and Renal Function after Burn Injury and Resuscitation

Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis

Clinical Outcome and Antimicrobial Therapeutic Drug Monitoring for the Treatment of Infections in Acute Burn Patients

Population Pharmacokinetic of Vancomycin Administered by Continuous Infusion in Critically Ill Patients

Mathematical Modeling, In-Human Evaluation and Analysis of Volume Kinetics and Kidney Function After Burn Injury and Resuscitation

A mathematical model for simulation of cardiovascular, renal, and hormonal responses to burn injury and resuscitation